The estimated Net Worth of Mary T Szela is at least $1.28 Million dollars as of 22 June 2020. Ms. Szela owns over 54,997 units of Coherus Biosciences Inc stock worth over $73,146 and over the last 17 years she sold CHRS stock worth over $984,580. In addition, she makes $226,402 as Independent Director at Coherus Biosciences Inc.
Sign up
Ms. Szela CHRS stock SEC Form 4 insiders trading
Mary has made over 17 trades of the Coherus Biosciences Inc stock since 2007, according to the Form 4 filled with the SEC. Most recently she exercised 54,997 units of CHRS stock worth $486,173 on 22 June 2020.
The largest trade she's ever made was exercising 54,997 units of Coherus Biosciences Inc stock on 22 June 2020 worth over $486,173. On average, Mary trades about 4,040 units every 97 days since 2007. As of 22 June 2020 she still owns at least 54,997 units of Coherus Biosciences Inc stock.
You can see the complete history of Ms. Szela stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mary Szela biography
Mary T. Szela serves as Independent Director of the Company. She has served as a member of our Board of Directors since July 2014. In January 2018, Ms. Szela was named Chief Executive Officer and President of Surefire Medical, Inc. (TriSalus LifeSciences) and currently serves on its board of directors. Mats L. Wahlström, a member of our Board of Directors, currently serves as Chairman of Surefire Medical, Inc. (TriSalus LifeSciences). From January 2016 to November 2016, Ms. Szela served as Chief Executive Officer of Aegerion Pharmaceuticals, Inc. and served on its board of directors. In November 2016, Aegerion Pharmaceuticals, Inc. merged with QLT Inc. to form Novelion Therapeutics Inc., where, until November 2017, Ms. Szela served as Chief Executive Officer and as a member of its board of directors. Ms. Szela served as the Chief Executive Officer of Melinta Therapeutics, Inc., an antibiotic development company, from April 2013 to August 2015. She has also served on the board of directors of Alimera Sciences, Inc. since June 2018, Kura Oncology, Inc. since October 2018, Melinta from January 2013 to August 2015, Receptos, Inc. from June 2014 to July 2015, Novo Nordisk from March 2014 to March 2017 and Suneva Medical, Inc. from July 2012 to 2017. Previously, Ms. Szela joined Abbott Laboratories in 1987 and held several leadership positions, including Senior Vice President of Global Strategic Marketing from January 2010 to May 2012 and Senior Vice President of U.S. Pharmaceuticals from September 2008 to December 2009. Prior to Abbott, Ms. Szela worked for the University of Illinois Hospital. Ms. Szela earned a B.S. in Nursing and an M.B.A. from the University of Illinois at Chicago. .
What is the salary of Mary Szela?
As the Independent Director of Coherus Biosciences Inc, the total compensation of Mary Szela at Coherus Biosciences Inc is $226,402. There are 8 executives at Coherus Biosciences Inc getting paid more, with Dennis Lanfear having the highest compensation of $5,361,710.
How old is Mary Szela?
Mary Szela is 57, she's been the Independent Director of Coherus Biosciences Inc since 2014. There are 10 older and 5 younger executives at Coherus Biosciences Inc. The oldest executive at Coherus Biosciences Inc is Dr. Barbara K. Finck M.D., 74, who is the Acting Chief Medical Officer.
What's Mary Szela's mailing address?
Mary's mailing address filed with the SEC is C/O KURA ONCOLOGY, INC., 12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO, CA, 92130.
Insiders trading at Coherus Biosciences Inc
Over the last 10 years, insiders at Coherus Biosciences Inc have traded over $94,360,509 worth of Coherus Biosciences Inc stock and bought 594,589 units worth $8,026,656 . The most active insiders traders include Llc Fmr, August J. Troendle, and James Healy. On average, Coherus Biosciences Inc executives and independent directors trade stock every 26 days with the average trade being worth of $64,928. The most recent stock trade was executed by Mats Wahlstrom on 1 February 2024, trading 59,988 units of CHRS stock currently worth $100,180.
What does Coherus Biosciences Inc do?
coherus biosciences is the leading biologics platform company solely focused on delivering high-quality biosimilar therapeutics that will expand patient access to life-changing medicines in regulated markets worldwide. founded in 2010, coherus is a late-stage biologics platform company focused on the global biosimilar market. headquartered in the san francisco bay area and composed of a team of industry veterans with decades of experience in pioneering biologics companies, our goal is to become a global leader in the biosimilar market by leveraging our team's collective expertise in key areas such as process science, analytical characterization, protein production and clinical-regulatory development. our commercialization partnerships include global pharmaceutical companies in europe, asia and latin america. biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and exp
What does Coherus Biosciences Inc's logo look like?
Complete history of Ms. Szela stock trades at Alimera Sciences, Coherus Biosciences Inc, Kura Oncology Inc, and Abbott Laboratories
Coherus Biosciences Inc executives and stock owners
Coherus Biosciences Inc executives and other stock owners filed with the SEC include:
-
Dennis Lanfear,
Chairman of the Board, President, Chief Executive Officer -
Jean-Frederic Viret,
Chief Financial Officer -
Dennis M. Lanfear,
Chairman, Pres & CEO -
Vincent Anicetti,
Chief Operating Officer -
Vladimir Vexler,
Chief Scientific Officer -
Vladimir Vexler,
Chief Scientific Officer -
Mats Wahlstrom,
Lead Independent Director -
V. Bryan Lawlis,
Independent Director -
Mary Szela,
Independent Director -
Ali Satvat,
Independent Director -
James Healy,
Independent Director -
Samuel Nussbaum,
Independent Director -
Kimberly Tzoumakas,
Director -
Thomas Fitzpatrick,
Chief Legal Officer -
Dr. Barbara K. Finck M.D.,
Acting Chief Medical Officer -
Richard L. Hameister,
Chief Quality Officer -
Michael Chen,
Sr. VP of Commercial Analytics & Trade -
Michael A. Fleming,
Chief Strategy Officer -
Rebecca Sunshine,
Exec. VP of HR -
Chris Thompson,
Exec. VP of Sales -
McDavid Stilwell,
Chief Financial Officer -
Alan C. Herman,
Chief Scientific Officer -
August J. Troendle,
Director -
Christos Richards,
Director -
Peter K. Watler,
Chief Technical Officer -
Barbara K Finck,
Chief Medical Officer -
Rita A Karachun,
-
Llc Fmr,
10% owner -
Biosimilar L.P.Kkr Biosimil...,
-
Eli & Co Lilly Ventures Fun...,
-
Sankyo Company, Ltd Daiichi,
-
Georgia Erbez,
-
Alan C Mendelson,
Director -
Lee Nisley Newcomer,
-
Mark Stolper,
-
Charles W. Newton,
-
Jill O'donnell Tormey,
-
Michael Lee Ryan,
-
Paul Reider,
Chief Commercial Officer -
Mc David Stilwell,
Chief Financial Officer -
Bryan J Mc Michael,
Chief Financial Officer